The Acute On Chronic Liver Failure (ACLF) drugs in development market research report provides comprehensive information on the therapeutics under development for Acute On Chronic Liver Failure (ACLF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute On Chronic Liver Failure (ACLF). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute On Chronic Liver Failure (ACLF) and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Acute On Chronic Liver Failure (ACLF) by 11 companies/universities/institutes. The top development phase for Acute On Chronic Liver Failure (ACLF) is preclinical with seven drugs in that stage. The Acute On Chronic Liver Failure (ACLF) pipeline has 14 drugs in development by companies and one by universities/ institutes. Some of the companies in the Acute On Chronic Liver Failure (ACLF) pipeline products market are: Genfit, Shanghai Hexaell Biotech and Shenzhen Wingor Biotechnology.
The key targets in the Acute On Chronic Liver Failure (ACLF) pipeline products market include Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25), NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain Containing 3 or NLRP3), and Toll Like Receptor 4 (hToll or CD284 or TLR4).
The key mechanisms of action in the Acute On Chronic Liver Failure (ACLF) pipeline product include Caspase (CASP or EC 3.4.22.) Inhibitor with one drug in Phase II. The Acute On Chronic Liver Failure (ACLF) pipeline products include eight routes of administration with the top ROA being Intravenous and three key molecule types in the Acute On Chronic Liver Failure (ACLF) pipeline products market including Small Molecule, and Cell Therapy.
Acute On Chronic Liver Failure (ACLF) overview
Acute-on-chronic liver failure occurs in patients with chronic liver disease and is characterized by acute deterioration of the patient requiring hospitalization and is associated with (1) hepatic and extrahepatic organ dysfunction, (2) systemic inflammation, and (3) a high 28-day mortality rate.
For a complete picture of Acute On Chronic Liver Failure (ACLF)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
